16 Mar
American College of Gastroenterology: Adalimumab
The importance of avoiding hospitalization was borne out by the fact that among 32 patients hospitalized in ACT 1 and ACT 2 trials, 11 required colectomies. According to Dr. Sand-born: A clinical trial of adalimumab (Humira, Abbott), another anti-TNF-a monoclonal antibody, used for patients with moderate-to-severe Crohn’s disease, demonstrated efficacy in inducing responses and remissions. [...]